At the ASCO 2019 annual meeting, trial investigator, Kazuhiko Nakagawa discusses RELAY: A multinational, double-blind, randomized Phase III study of erlotinib in combination with ramucirumab or placebo in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NCT02411448).
Questions
1. What is the rationale for the use of ramucirumab plus erlotinib in metastatic EGFR-mutated non-small cell lung cancer (NSCLC)? (0:03)
2. Could you tell us a little about the RELAY study and its findings? (0:48)
3. What was the safety profile of ramucirumab plus erlotinib? (1:43)
4. Which patients are most likely to respond to this therapy? (2:49)
5. Following the success of the RELAY and REVEL studies, what will be the next steps in the clinical development of ramucirumab in NSCLC? (3:55)
Speaker disclosure: Kazuhiko Nakagawa has acted as a consultant for AstraZeneca, Eli Lilly, Boehringer Ingelheim and Roche.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
